Showing 51 to 75 of 131 Results
Page 1 | 2 | 3 | 4 | 5 | 6
First Australian Patients Enrolled in Gore Global Registry for Endovascular Aortic Treatment
20 March 2012 - Royal Prince Alfred Hospital First in Australia

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore Announces First Patient Enrolled in Gore REVISE Clinical Study
17 September 2008 - IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)

Gore Launches Early Cannulation Capable GORE® ACUSEAL Vascular Graft
19 November 2013 - Results of early cannulation clinical trial presented at the 2013 VEITHsymposium

SVS and Gore Support Increasing Numbers of Women in Vascular Surgery
23 May 2012 - Women’s Leadership to Take Spotlight at the Society for Vascular Surgery 2012 Vascular Annual Meeting

Gore and AAAneurysm Outreach Partner to Increase Early Detection of Abdominal Aortic Aneurysm (AAA)
28 January 2014 - New Campaign Will Employ Awareness, Community Outreach, and Patient Screening to Fight AAA

GORE Flow Reversal System Cleared by FDA
09 February 2009 - Breakthrough system provides neuroprotection during carotid artery stenting by reversing blood flow at the treatment site and continuously directing emboli away from the brain


Gore Launches Lower Profile GORE® EXCLUDER® AAA Endoprosthesis Contralateral Leg Components in US and Europe
11 March 2013 - Addition to Series of Reduced Profile GORE® EXCLUDER® Devices Launching This Year

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

GORE® Hybrid Vascular Graft Commercially Available in the United States
01 June 2011 - W. L. Gore & Associates today is announcing commercial availability in the US of the GORE® Hybrid Vascular Graft.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

GORE® C3 Delivery System Approved In Japan
03 December 2013 - System Enables Physicians and Interventionalists to Reposition GORE® EXCLUDER® AAA Endoprosthesis for Ideal Placement in Treating Abdominal Aortic Aneurysms

Gore Participates in FDA Circulatory System Devices Advisory Panel Meeting
07 June 2012 - Focus on Safety and Effectiveness of GORE® HELEX® Septal Occluder for Closure of Atrial Septal Defect (ASD)

Gore REVISE Clinical Study Demonstrates Superiority of GORE VIABAHN Endoprosthesis
20 February 2014 - GORE Device Outperforms Standard Treatment Option for Stenoses or Thrombotic Occlusions

W. L. Gore & Associates Marks 12th Year as One of Nation’s Best
22 January 2009 - Company Earns #15 Position on FORTUNE’S 2009 “100 Best Companies to Work For” List

Gore Receives CE Mark for New GORE® EXCLUDER® AAA Endoprosthesis Sizing Options
03 July 2012 - Broader Range of Sizes Now Accommodates More Patient Anatomies

Gore Delivers New Choice for Complex Soft Tissue Reinforcement
04 October 2010 - Economical Alternative to Biologics, Now In Larger Sizes

Nominees Announced for 2013-2014 Pioneers in Performance Awards for Europe; Online Voting Opens at PioneersInPerformance.com
06 April 2013 -

Awards Program Sponsored by W. L. Gore & Associates Honors Medical Specialists Advancing Therapy and Improving Patient and Clinical Performance Through Active Collaboration


Gore Announces First Patient Enrolled in Gore REVISE Clinical Study
17 September 2008 - IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)

Gore Receives Zero Reports of Erosion Associated With GORE® HELEX® Septal Occluder
22 August 2011 - W. L. Gore & Associates (Gore) today reported that it has received zero accounts of erosion of the aortic root or the free wall of the atrium associated with the worldwide use of the GORE® HELEX® Septal Occluder.

W. L. Gore & Associates Presents New Data and Clinical Updates at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2008
08 October 2008 - Gore continues commitment to clinical research with symposia, ongoing clinical studies and emerging technologies

Gore Announces Broadened FDA Indication for GORE VIABAHN® Endoprosthesis for Iliac Occlusive Disease
17 September 2008 - Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries

FDA Approves GORE® VIABAHN® Endoprosthesis for Revision of the Arteriovenous Access
11 December 2013 - Flexibility and Durability to Aid Hemodialysis Patients


Gore Presents Astronaut and Scientist Mae C. Jemison, MD, as Keynote Speaker at Women in Vascular Leadership Luncheon
18 March 2014 - The pioneering Dr. Jemison, who flew aboard the Space Shuttle Endeavour, will address vascular surgeons at the 2014 SCVS symposium in Carlsbad, Calif.

W. L. Gore & Associates Announce First Patient Enrolled in Gore EMBOLDEN Clinical Study
16 January 2009 - Multi-center study will evaluate safety and efficacy of the GORE Embolic Filter in carotid stenting for high risk surgical patients

Gore Receives CE Mark for GORE® Hybrid Vascular Graft
16 August 2012 - More than 2500 Successful Implants for Dialysis Access and Other Vascular Procedures

Gore Launches Study of Early TIPS Therapy for Ascites Patients
01 November 2010 - Experts Call for Fresh Look at Transjugular Intrahepatic Portosystemic Shunt (TIPS) Therapy for Liver Disease Patients

Gore Joins Vascular and Endovascular Physicians in Honoring 2013 Pioneers in Performance Winners for Latin America
29 April 2013 - Leading Practitioners and Researchers from Mexico, Central and South America CICE 2013

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Rush University Medical Center First to Enroll Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
11 December 2008 - Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke

Gore Showcases New Endovascular Repair Simulation Technology at VIVA
18 October 2011 - Physicians Simulate Real Patient Cases Ushering New Era of Procedure Preparation

Vascular Surgeons Present Positive Study Results for the GORE PROPATEN® Vascular Graft and Updates to the GORE VIABAHN® Endoprosthesis
17 September 2009 - Physicians report new information at the Society for Vascular Surgery's annual meeting

New 10 cm GORE® Hybrid Vascular Graft Delivers Unprecedented Versatility
14 November 2012 - Increased Length of Nitinol Reinforced Section Allows for Access to Deeper Vessels, Extends Landing-Zone Positioning Options

Gore Receives CE Mark for GORE® PROPATEN® Vascular Graft for Hemodialysis Access
22 February 2011 - Unique Vascular Graft Transcends Mechanical Solutions for Dialysis Access

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

W. L. GORE & Associates Named a Top U.S. Workplace
16 January 2014 - Company has appeared in every listing of the “100 Best Companies to Work For”

England National Institute for Health Research Stroke Research Network Adopts Gore REDUCE Clinical Study
19 June 2012 - Study Investigates Device Closure of Patent Foramen Ovale (PFO) in Stroke Reduction.

W. L. Gore & Associates Continues its Tradition As One of Nation’s Best Workplaces
25 January 2010 - Company Ranks No. 13 on FORTUNE’S 2010 “100 Best Companies to Work For” List

First Patient Enrolled in GORE® Septal Occluder Clinical Study for Atrial Septal Defect
19 October 2012 - Pivotal Multicenter Trial Begins at Duke University, Evaluating Safety and Efficacy of Innovative ASD Closure Device

W. L. Gore & Associates Continues its Tradition as One of Nation's Best Workplaces
20 January 2011 - Company Earns 14th Consecutive Appearance on FORTUNE’S "100 Best Companies to Work For" List

Gore Reports First Patient Treated using GORE® C3 Delivery System for GORE® EXCLUDER® AAA Endoprosthesis
11 January 2011 - New medical innovation repositions the future of endovascular repair for abdominal aortic aneurysm

Gore Reaffirms Commitment to Stroke Study, Launches Online Resource
15 November 2010 - Cardiology and Neurology Investigators Support Continued Study of Patent Foramen Ovale (PFO)

Gore Medical Receives National Honor for Operational Excellence
20 June 2013 - W. L. Gore & Associates named as a winner of the eighth annual Pinnacle Award

First Patient Enrolled in Gore® SCAFFOLD Clinical Study for Carotid Stenting
12 September 2013 - Pivotal Multicenter Investigational Study Begins at Medical University of South Carolina (MUSC), Evaluating Safety and Efficacy of Innovative GORE® Carotid Stent

First Patient Enrolled in Study Evaluating Performance of Spectranetics Laser Ablation Followed by GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
25 February 2008 - Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.

Endovascular Repair of Descending Thoracic Aortic Aneurysm
25 October 2007 - On November 6, 2007, at 3 pm (EST) surgeons and radiologists from the University of Michigan Health System will perform a descending thoracic aortic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis.

Gore Acquires Intellectual Property of NMT Medical, Inc.
19 October 2011 - CLOSURE I Trial Data May Create Better Clinical Understanding of Patent Foramen Ovale (PFO) in Stroke Patients

Gore Receives FDA Approval for Next Generation of Large Diameter GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.

Gore REDUCE Clinical Study Principal Investigators Respond to Recent RESPECT Clinical Trial and PC Trial Results
15 November 2012 - Gore REDUCE Clinical Study Investigators Implored to Continue Enrollment, Drive 'Diligent Continuation of Study'


Gore Receives FDA Approval for Modification of GORE VIABAHN® Endoprosthesis
17 September 2008 - Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries.

GORE® EXCLUDER® Iliac Branch Endoprosthesis Is First Dedicated System of Its Kind Approved in Europe
07 November 2013 -

First Successful Implants Completed in Italy and the United Kingdom, Providing Endovascular Repair to Iliac Arteries



Gore Announces New Configuration of GORE BIO-A® Tissue Reinforcement for Hiatal Hernia Repair
15 June 2008 - Gore adds thinner, more flexible, custom size bioabsorbable product

Gore Receives CE Mark Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
27 April 2010 - Expanded indication enables stent removal for up to 12 months following implantation for effective treatment of both malignant and benign biliary strictures.


Gore Announces European Availability of Next Evolution of GORE® VIABAHN® Endoprosthesis
19 January 2011 - Lower profile delivery system in Europe provides more options for endoluminal bypass

New Clinical Evidence Supporting Efficacy of GORE® PROPATEN® Vascular Graft
19 January 2011 - Jes Lindholt, MD, PhD presented new study data from a Scandinavian clinical trial designed to compare patency rates of the GORE PROPATEN Vascular Graft with standard ePTFE grafts (GORE-TEX® Stretch Vascular Graft).

Clinical Investigators Address Confusion Over Study of Patent Foramen Ovale (PFO) in Stroke Patients
13 December 2010 - W. L. Gore & Associates today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.

GORE® Septal Occluder Honored as Best In Show and Gold Winner in the 2013 Medical Design Excellence Awards
26 June 2013 - Recognition for Innovation in Expanding Treatment Options for Patients

Gore Receives First FDA Approval for Endovascular Repair of Aortic Dissection
11 September 2013 - Conformable GORE® TAG® Thoracic Endoprosthesis First to Receive Indication for Aneurysm, Trauma and Dissection

Gore Receives CE Mark for GORE PRECLUDE® Vessel Guard
06 May 2008 - Distinguished seal allows biomaterial to be used across the European Union

Gore Receives Approval to Market GORE TAG® Thoracic Endoprosthesis in Japan
03 June 2008 - Expedited Clearance Provides Less Invasive Treatment Alternative for Thoracic Aortic Aneurysms

Royal Sussex County Hospital First in the UK to Enroll a Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
01 November 2011 - International study to demonstrate safety, effectiveness of GORE® HELEX® Septal Occluder for PFO closure in patients with a history of cryptogenic stroke

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

Improved GORE® DrySeal Sheath with Hydrophilic Coating Allows for Smooth and Minimally Invasive Endovascular Repair
18 December 2012 - Engineered to Increase Sheath Lubricity and Minimize Coating Particulation for Easier Insertion and Removal in Treatment of Patients with AAA and TAA


Gore Recognizes Physicians as “Pioneers in Performance” for Exceptional Work in the Field of Endovascular Therapy
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients

First Patient Enrolled in Gore EXCLUDER Iliac Branch Study
14 November 2013 - Multi-Center Study to Assess Safety and Effectiveness of GORE® EXCLUDER® Iliac Branch Endoprosthesis for Treatment of Common Iliac Artery Aneurysms (CIAA) or Aorto-Iliac Aneurysms (AIA).

First Patient Enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study
27 January 2014 - Multi-Center Study to Assess Feasibility of Gore Device to Treat Historically Challenging Patient Population

GORE® Hybrid Vascular Graft Honored as Gold Winner in the 2012 Medical Design Excellence Awards
03 July 2012 - W. L. Gore & Associates (Gore) today announced that the GORE® Hybrid Vascular Graft was awarded Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA) competition.

Gore Receives Approval from FDA for Unique Patent Foramen Ovale Stroke Study
05 May 2008 - Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management

Gore Reacts to RESPECT Trial Results
26 October 2012 - Data Calls for Further Research on Transcatheter Patent Foramen Ovale (PFO) Closure

Gore Announces FDA Approval of Next Evolution of GORE® VIABAHN® Endoprosthesis
17 February 2011 - Lower profile delivery system in the US provides more options for endoluminal bypass

Gore Receives Health Canada Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
17 January 2011 - New treatment option now available for benign and malignant biliary strictures

Gore Receives FDA Approval for Innovative GORE® C3 Delivery System for GORE® EXCLUDER® AAA Endoprosthesis
04 January 2011 - New innovation enables physicians and interventionalists to reposition device for ideal placement in treating abdominal aortic aneurysms.

Gore Prevails in Heart Device Patent Infringement Suit
05 August 2013 - W. L. Gore & Associates (Gore) today announced a favorable ruling involving the GORE® HELEX® Septal Occluder.

Gore Receives FDA Approval for 25 cm GORE® VIABAHN® Endoprosthesis
06 November 2013 - Longest stent-graft introduced in the United States

Showing 51 to 75 of 131 Results
Page 1 | 2 | 3 | 4 | 5 | 6